Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Yesterday
Higher intakes of tofu, soy protein and soy isoflavones, but not total legumes or total soy, appear to reduce the risk of developing type 2 diabetes (T2D), suggests a study.
6 days ago
Treatment with direct oral anticoagulant (DOAC) plus P2Y12 inhibitor (dual therapy) in adults with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) reduces bleeding risk compared with vitamin K antagonist plus aspirin and P2Y12 inhibitor (triple therapy), suggest a study.
4 days ago
Ipragliflozin appears to be an effective renoprotective agent in patients with type 2 diabetes, a new study has found.

Protecting vulnerable populations from pertussis: The current climate and the role of maternal immunisation

20 Feb 2020
Infants are a vulnerable population in which exposure to pertussis can befatal. Dr Polly Po-Ki Ho and Professor Michael Desmond Nissen discuss thecurrent epidemiological climate of pertussis in infants and how best toprotect this population through maternal immunisation.



The material is for the reference and use by healthcare professionals only.
Please read the full prescribing information prior to administration. Full prescribing information is available upon request from GlaxoSmithKline Limited – 23/F, Tower 6, The Gateway, 9 Canton Road, Tsimshatsui, Kowloon, Hong Kong
For adverse event reporting, please call GlaxoSmithKline Limited at (852) 3189 8989 (Hong Kong)
The contents and opinions expressed in its entirely herein are solely those of the presenter, and might contain usage indications not officially approved in Hong Kong. Although every care has been taken by the sponsor and publisher to ensure technical accuracy and reporting in full, no responsibility is accepted for errors or omission. Before prescribing any products mentioned, please consult the Hong Kong-approved prescribing information issued by the manufacturer.
© 2019 GSK group of companies or its licensor

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Yesterday
Higher intakes of tofu, soy protein and soy isoflavones, but not total legumes or total soy, appear to reduce the risk of developing type 2 diabetes (T2D), suggests a study.
6 days ago
Treatment with direct oral anticoagulant (DOAC) plus P2Y12 inhibitor (dual therapy) in adults with nonvalvular atrial fibrillation (AF) after percutaneous coronary intervention (PCI) reduces bleeding risk compared with vitamin K antagonist plus aspirin and P2Y12 inhibitor (triple therapy), suggest a study.
4 days ago
Ipragliflozin appears to be an effective renoprotective agent in patients with type 2 diabetes, a new study has found.